IQVIA’s Christina Mack Named 2023 PharmaVoice 100 Honoree

 

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, announced that Dr. Christina Mack, chief scientific officer, has been named to the 2023 PharmaVoice 100 list.

The PharmaVoice 100, an industry-acclaimed honor now in it’s 18th year, recognizes trailblazers and leaders who have built and mentored innovative teams, developed breakthrough strategies, and worked toward solutions that improve the lives of patients and shape the future of life sciences.

“As our Chief Scientific Officer, Christina is passionate about accelerating innovation in healthcare through the use of real world data to enable evidence-based decision-making,” said IQVIA Chairman and CEO Ari Bousbib. “She is consistently focused on moving our industry forward, tackling challenges in a creative and innovative way, and making a positive impact on patients and population health.”

“This industry is a ground-breaking one capable of changing the world through science and technology. Christina Mack and her fellow honorees inspire advancements by guiding their teams, supporting their patients, and propelling their organizations’ missions forward. We are excited to recognize their contributions through this annual list,” said Meagan Parrish, lead editor of PharmaVoice.

Dr. Mack, an engineer and epidemiologist by training, was recognized by her peers for her passion toward innovation, her ability to form and mentor teams, and her scientific and technical expertise. Also highlighted was her ability to balance science with practical operations to achieve results, both through establishing large, innovative programs as well as translating analytic results to enable evidence-based decision-making. Dr. Mack’s work during the COVID-19 pandemic was particularly impactful, illustrated by her team’s recent UNIVANTS award for healthcare excellence alongside the National Basketball Association (NBA) for their work on the NBA Bubble and also through her global engagements with elite U.S. sports leagues and the Tokyo 2020 Olympics.

“This award is an incredible honor, and reflects the brilliance and hard work of the teams here at IQVIA as well as our clients and partner organizations. The work we do together is pushing new boundaries in science and technology to improve population health and patient outcomes,” said Dr. Mack. “We are at such a critical moment in our field, where science and technology are converging to accelerate and improve healthcare. I am grateful to be in a place where we are able to move the needle for patients and for our industry.”

The 2023 PharmaVoice 100 honorees were celebrated during a virtual two-day event PharmaVoice hosted with its sister publication BioPharmaDive called “The Next Frontier of the Life Sciences” on Oct. 25-26.

Read more about Dr. Mack’s recognition here.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Contacts

Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)
+1.973.316.3828

Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)
+1.919.780.3221

 
 

Source: IQVIA

Back to news